TP53 and renal cell carcinoma: A recent preclinical study reported that an mTOR 1/2 dual inhibitor combined with the autophagy inhibitor 3-methyaldenine resulted in a good outcome in an RCC model.26 Under drug-induced autophagy conditions, it remains to be determined whether TGase 2 is induced for p53 depletion through autophagy.